646 related articles for article (PubMed ID: 27657341)
21. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
Ludovini V; Gori S; Colozza M; Pistola L; Rulli E; Floriani I; Pacifico E; Tofanetti FR; Sidoni A; Basurto C; Rulli A; Crinò L
Ann Oncol; 2008 May; 19(5):883-90. PubMed ID: 18187484
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
23. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
24. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
26. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
27. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Abdel-Fatah TM; McArdle SE; Johnson C; Moseley PM; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Br J Cancer; 2014 May; 110(10):2450-61. PubMed ID: 24755885
[TBL] [Abstract][Full Text] [Related]
28. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer.
Ponzone R; Montemurro F; Maggiorotto F; Robba C; Gregori D; Jacomuzzi ME; Kubatzki F; Marenco D; Dominguez A; Biglia N; Sismondi P
Ann Oncol; 2006 Nov; 17(11):1631-6. PubMed ID: 16980602
[TBL] [Abstract][Full Text] [Related]
30. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
[TBL] [Abstract][Full Text] [Related]
31. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
Walter V; Fischer C; Deutsch TM; Ersing C; Nees J; Schütz F; Fremd C; Grischke EM; Sinn P; Brucker SY; Schneeweiss A; Hartkopf AD; Wallwiener M
Breast Cancer Res Treat; 2020 Aug; 183(1):137-144. PubMed ID: 32613540
[TBL] [Abstract][Full Text] [Related]
32. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
33. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
Robertson S; Acs B; Lippert M; Hartman J
Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
[TBL] [Abstract][Full Text] [Related]
34. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.
Purdie CA; Quinlan P; Jordan LB; Ashfield A; Ogston S; Dewar JA; Thompson AM
Br J Cancer; 2014 Feb; 110(3):565-72. PubMed ID: 24300977
[TBL] [Abstract][Full Text] [Related]
35. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
36. A nomogram to predict individual prognosis in node-negative breast carcinoma.
Mazouni C; Spyratos F; Romain S; Fina F; Bonnier P; Ouafik LH; Martin PM
Eur J Cancer; 2012 Nov; 48(16):2954-61. PubMed ID: 22658808
[TBL] [Abstract][Full Text] [Related]
37. Dietary acrylamide intake and estrogen and progesterone receptor-defined postmenopausal breast cancer risk.
Pedersen GS; Hogervorst JG; Schouten LJ; Konings EJ; Goldbohm RA; van den Brandt PA
Breast Cancer Res Treat; 2010 Jul; 122(1):199-210. PubMed ID: 19949857
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer.
Zegarac M; Nikolic S; Gavrilovic D; Jevric M; Kolarevic D; Nikolic-Tomasevic Z; Kocic M; Djurisic I; Inic Z; Ilic V; Santrac N
J BUON; 2013; 18(4):859-65. PubMed ID: 24344009
[TBL] [Abstract][Full Text] [Related]
39. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
40. Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays.
Bae YK; Gong G; Kang J; Lee A; Cho EY; Lee JS; Suh KS; Lee DW
Am J Surg Pathol; 2012 Dec; 36(12):1817-25. PubMed ID: 23154769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]